NCT02806648View on ClinicalTrials.gov

A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

July 31, 2017

Study Completion Date

January 31, 2018

Conditions
Pancreatic Neuroendocrine Cancer
Interventions
DRUG

Palbociclib

Palbociclib

Trial Locations (9)

12002

H. Castellon, Castelló

Unknown

ICO, L'Hospitalet de Llobregat

C. H. de Navarra, Pamplona

H.U.C de Asturias, Oviedo

H. Vall d´Hebron, Barcelona

H U Ramón y Cajal, Madrid

H. 12 Octubre, Madrid

H.U.La Paz, Madrid

H.U.Virgen del Rocio, Seville

All Listed Sponsors
lead

Grupo Espanol de Tumores Neuroendocrinos

OTHER

NCT02806648 - A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET) | Biotech Hunter | Biotech Hunter